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Abstract
Background: There is a high prevalence of rare genetic disorders in the Middle East, and their study provides
unique clinical and genetic insights. Autosomal recessive polycystic kidney disease (ARPKD) is one of the leading
causes of kidney and liver-associated morbidity and mortality in Oman. We describe the clinical and genetic profile
of cohort of ARPKD patients.
Methods: We studied patients with a clinical diagnosis of ARPKD (n = 40) and their relatives (parents (n = 24) and
unaffected siblings (n = 10)) from 32 apparently unrelated families, who were referred to the National Genetic
Centre in Oman between January 2015 and December 2018. Genetic analysis of PKHD1 if not previously known was
performed using targeted exon PCR of known disease alleles and Sanger sequencing.
Results: A clinical diagnosis of ARPKD was made prenatally in 8 patients, 21 were diagnosed during infancy (0–1
year), 9 during early childhood (2–8 years) and 2 at later ages (9–13 years). Clinical phenotypes included polycystic
kidneys, hypertension, hepatic fibrosis and splenomegaly. Twenty-four patients had documented chronic kidney
disease (median age 3 years). Twenty-four out of the 32 families had a family history suggesting an autosomal
recessive pattern of inherited kidney disease, and there was known consanguinity in 21 families (66%). A molecular
genetic diagnosis with biallelic PKHD1 mutations was known in 18 patients and newly identified in 20 other
patients, totalling 38 patients from 30 different families. Two unrelated patients remained genetically unsolved. The
different PKHD1 missense pathogenic variants were: c.107C > T, p.(Thr36Met); c.406A > G, p.(Thr136Ala); c.4870C > T,
p.(Arg1624Trp) and c.9370C > T, p.(His3124Tyr) located in exons 3, 6, 32 and 58, respectively. The c.406A > G,
p.(Thr136Ala) missense mutation was detected homozygously in one family and heterozygously with a c.107C > T,
p.(Thr36Met) allele in 5 other families. Overall, the most commonly detected pathogenic allele was c.107C > T;
(Thr36Met), which was seen in 24 families.
Conclusions: Molecular genetic screening of PKHD1 in clinically suspected ARPKD cases produced a high
diagnostic rate. The limited number of PKHD1 missense variants identified in ARPKD cases suggests these may be
common founder alleles in the Omani population. Cost effective targeted PCR analysis of these specific alleles can
be a useful diagnostic tool for future cases of suspected ARPKD in Oman.
Keywords: Autosomal recessive polycystic kidney disease (ARPKD), Polycystic kidney and hepatic disease 1 (PKHD1),
Hepatic fibrosis, molecular diagnosis, Founder alleles
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Background
Autosomal recessive polycystic kidney disease (ARPKD)
is one of the most frequent cystic kidney diseases in in-
fants and children, causing kidney and liver associated
mortality and morbidity. The estimated incidence of
ARPKD is 1:6000 to 1:55,000 births [1]. Classically,
ARPKD manifests prenatally as enlarged echogenic kid-
neys with Potter’s syndrome or postnatally during child-
hood or adolescence with polycystic kidney disease and
congenital hepatic fibrosis. It is characterized by bilateral
echogenic cystic kidneys caused by dilatation of the renal
tubular collecting ducts and congenital hepatic fibrosis
secondary to malformation of the liver biliary ducts.
ARPKD is also associated with systemic and portal
hypertension. Current therapies focus on treating ARPK
D symptoms [2].
ARPKD is caused by mutations in the polycystic
kidney and hepatic disease 1 (PKHD1) (OMIM
606702), which is located on chromosome 6 (p12.3-
p12.2). Consistent with the disease phenotype, high
expression of PKHD1 is found in fetal and adult kid-
ney, with low levels detected in the liver, pancreas
and arterial walls [3]. The longest open reading frame
transcript (NM_138694.4) contains 67 exons and en-
codes a 4074 amino acid protein called fibrocystin /
polyductin. Fibrocystin is an integral membrane pro-
tein that is localized to the basal bodies of primary
cilia in epithelial cells and hypothesized to control
kidney tubular formation by modifying polycystin-2
expression [4]. It was shown that the severity of
ARPKD is determined by the type of mutations rather
than the location on the PKHD1 gene [5]. There are
over 700 different mutations associated with an ARPK
D phenotype [6].
The importance of early diagnosis and management of
ARPKD through genetic testing is widely recognized [7].
Precise molecular genetic diagnosis can improve the
clinical management of patients, avoiding the exposure
to unnecessary and invasive investigations and enhance
early detection of kidney and extrarenal complications.
The size of PKHD1 and its heterogeneous mutational
spectrum has previously been an obstacle to molecular
genetic diagnosis. However, recent advances in massive
parallel sequencing / next generation sequencing (NGS)
have facilitated routine large scale screening for patho-
genic mutations in PKHD1.
In addition to mutations in PKHD1, mutations in
DZIP1L (OMIM 671570) may underlie ARPKD. Patho-
genic variants have been identified in multiple unrelated
consanguineous Turkish, Palestinian and Egyptian pa-
tients with ARPKD and a moderate renal phenotype [8].
DZIP1L encodes for DAZ-interacting zinc finger protein
1-like protein (DZIP1L) that is located in the centrioles
and the distal ends of basal bodies [8].
Inherited kidney disease is a leading cause of end
stage kidney disease (ESKD) in children in Oman [7].
In one Omani hospital-based study, the observed
birth incidence of ARPKD was evaluated to be much
higher than typical, estimated to be 1 in 12,000 births
[9]. However, this number was from a selected hos-
pital population and there are no population-based
studies evaluating the incidence of ARPKD in the
Omani population as a whole. A recent study from
Oman showed that hereditary kidney disease accounts
for 32% of etiologies causing chronic kidney disease
(CKD) in children and ARPKD is the leading cause,
accounting for 12% of CKD [10]. The objective of this
study was to investigate the clinical features and the
molecular genetic diagnosis in patients with suspected
ARPKD in an Omani population.
Methods
Patients sampling and ethical approval
A group of 40 affected patients, 10 unaffected siblings
and 24 parents, from 32 unrelated families were re-
ferred to the National Genetic Centre in Oman be-
tween January 2015 and December 2018 for the
genetic study of ARPKD from the Royal Hospital
(n = 31), Sohar Hospital (n = 8), Rustaq Hospital (n =
1) and Al Buraimi Hospital (n = 1). Clinical informa-
tion, including age at clinical diagnosis, use of neo-
natal ventilation, presence of cystic kidney disease,
stage of CKD, splenomegaly, hypertension, urinary
concentration defect, urinary tract infection (UTI),
pulmonary hypoplasia, oesophageal varices and renal
replacement modalities were extracted from the pa-
tient’s medical files at the time of genetic testing and
were analyzed. Congenital hepatic fibrosis was diag-
nosed based on clinical parameters, abdominal ultra-
sonography and where available, pathological results
from liver biopsy specimens. The system used for
CKD staging is according to that published by the
National Kidney Foundation’s Kidney Disease Out-
come Quality Initiative KDOQI in 2003 [11].
Additional demographic information including familial
history of ARPKD, parental consanguinity and geograph-
ical distribution were also obtained. Family pedigrees de-
scribed in this study were drawn using invitae online
tool (https://familyhistory.invitae.com) (Supplementary
Figure S1). We have previously reported family struc-
tures (but not clinical details) for 5 of these families with
genetically proven ARPKD [12].
This study was ethically approved by the Research and
Ethical Review and Approval Committee, Ministry of
Health in Oman and by the Ethics Committee, College
of Medicine and Health Sciences, Sultan Qaboos Univer-
sity in Oman (MREC#1096). All study participants pro-
vided written informed consent.
Alawi et al. BMC Nephrology          (2020) 21:347 Page 2 of 11
Mutational analysis
DNA was extracted manually from the peripheral blood
lymphocytes of patients and family members using
QIAamp DNA mini kit (QIAGEN). For 18 unrelated pa-
tients, molecular study had been previously performed
through NGS using targeted gene panel that includes
cystic kidney disease genes (including PKD1, PKD2,
PKHD1, HNF1B) (Table S1) [12]. These 18 patients all
had biallelic variants in PKHD1 but mutations were lim-
ited to 4 alleles [12]. Based on these previous NGS re-
sults, Sanger sequencing screening of the PKHD1 exons
3, 6, 32 and 58 was performed for another 22 patients
from 14 different families with clinically suspected
ARPKD. For the confirmation of segregation of variants
within families, the available samples of parents, siblings
and relatives were also screened using Sanger sequen-
cing (Table 2, Supplementary Figure S1).
For Sanger sequencing, target regions were amplified
using AmpliTaq Gold 360 Master Mix kit (Applied Bio-
systems) and oligonucleotide primers, which were de-
signed using the Primer3 program (http://primer3.ut.ee/
). Oligonucleotide primers were designed to cover the
whole exon sequence at which variant is located. For
large exons, a set of overlapping fragments were ampli-
fied using multiple oligonucleotide primer pairs (Supple-
mentary Table S2).
PCR was carried out using the following conditions:
denaturation at 95 °C for 15 min; followed by 13 cycles
of 94 °C for 30 s, 62 °C for 30 s and 72 °C for 30 s;
followed by 8 cycles of 94 °C for 30 s, 46.5 °C for 30 s and
72 °C for 30 s; followed by 16 cycles of 94 °C for 30 s,
54.5 °C for 30 s and 72 °C for 30 s, amplification for a
total of 37 cycles, and then elongation at 72 °C for 5 min.
PCR products were purified using BigDye Terminator
Cycle Sequencing kit (PE Applied Biosystems, Massa-
chusetts, USA) and sequenced (automated ABI 3130).
Sequencing results were aligned and analyzed by com-
parison with the human reference sequence of the
PKHD1 gene (NM_138694.3) using the SequencePilot
4.2.2 software (JSI Medical Systems GmbH). For genetic
analysis all PKHD1 variants were classified with regard
to pathogenicity according to the revised criteria of the
American College of Medical Genetics [13].
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 20, with the results expressed as frequencies and
percentage for categorical variables and as mean and
median for continuous variables, as appropriate.
Results
Clinical characteristics
In total, 32 unrelated families were included in this study
(Table 1). The cohort includes 40 clinically suspected
ARPKD patients (n = 19 males and n = 21 females), 24
parents and 10 unaffected siblings.
Molecular genetic diagnosis of biallelic PKHD1 muta-
tions was previously known in 18 patients described here
and newly identified in a further 20 patients from a total
of 30 different families, giving an overall mutation detec-
tion rate of 94% in our cohort of clinically suspected
ARPKD (Table 2). Twenty-four families (75%) reported
a known family history of kidney disease consistent with
an autosomal recessive inheritance pattern. Two families
remained genetically unsolved, both had no family his-
tory of kidney or liver disease. Parental consanguinity
was known in 21 families (66%) in keeping with high
rates of autosomal recessive disease in Oman.
The initial clinical diagnosis was made prenatally in
eight patients (20%), during infancy (0–1 year) in 21
patients (52.5%), during early childhood (1–8 years) in
9 patients (22.5%), and in later years (9–13 years) in 2
patients (5%) (Table 1). At the time of molecular
diagnosis, clinical features were documented, includ-
ing systemic hypertension (72.5%), suspected congeni-
tal hepatic fibrosis (CHF) (77.5%), CKD (60%) with a
median age of onset 3 years, splenomegaly (47.5%),
pulmonary hypoplasia (17.5%) and perinatal / post-
neonatal death due to respiratory failure (15%) (Table
1). Twelve of patients (27.5%) developed ESKD at me-
dian age of 13 years.
Table 1 Clinical characteristics of suspected ARPKD patients
from Oman
N %
ARPKD patients 40 100
Males 19 48
Females 21 53
Age at diagnosis:
Prenatal 8 20
Birth-1st month 6 15
2–12 months 15 37.5
1–8 years 9 22.5
> 8 years 2 5
Clinical Features:
Systemic hypertension 29 72.5
Congenital hepatic fibrosis 31 77.5
Splenomegaly 19 47.5
Pulmonary hypoplasia 7 17.5
Perinatal deaths (< 28 days) 4 10
Postneonatal deaths (28 days - 1 year) 2 5
Chronic Kidney Disease 24 60
End Stage Kidney Disease 12 30
ARPKD Autosomal recessive polycystic kidney disease, N Number;
%, percentage
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Genetics of Omani ARPKD patients
Our previous NGS study of inherited cystic kidney dis-
eases had identified 4 PKHD1 missense pathogenic
mutations [12] in 18 patients with suspected ARPKD.
These included c.107C > T, p.(Thr36Met); c.406A > G,
p.(Thr136Ala); c.4870C > T, p.(Arg1624Trp) and
c.9370C > T, p.(His3124Tyr) located in exons 3, 6, 32
and 58, respectively. These alleles were found either ho-
mozygously or heterozygously in 20 other patients with
clinically suspected ARPKD (Table 2). In total, twenty-
one families (66%) carried homozygous alleles, while 9
(28%) carried compound heterozygous alleles. The most
commonly detected mutation in PKHD1 was
p.(Thr36Met), where 16 families carried it in homozy-
gous state, while 8 families were compound heterozy-
gous for this allele combined with the p.(Thr136Ala)
allele (5 families) or the p.(Arg1624Trp) allele (3 fam-
ilies). Four families carried the homozygous mutation
p.(Arg1624Trp), whilst one family carried the homozy-
gous mutation p.(Thr136Ala). One family had com-
pound heterozygous mutations p.(Arg1624Trp) and
p.(His3124Tyr). The clinical presentations and genotypes
are summarized in Table 2. Sanger sequencing chro-
matograms of the four different mutations in the
PKHD1 gene are shown in Supplementary Figure S2A.
The p. (Thr136Ala) has not been reported outside Oman
and is absent from reference databases (Table 3).
Geographic distribution of PKHD1 mutations in Oman
The p.(Thr36Met) allele was detected in patients from
all governorates of the country except, Musandam, Al
Wusta and Dhofar (Fig. 1). The missense p.(Thr136Ala)
allele was detected in its homozygous state in one family
from Al Batinah South and in heterozygous state in fam-
ilies from Ad Dakhiliyah (n = 1), Al Dhahirah (n = 2)
and Al Batinah south (n = 2) (Fig. 1). We postulate that
this mutation may be a founder allele in this population.
Discussion
Inherited kidney diseases, including ARPKD are leading
causes of CKD and ESKD in children in Oman, leading
to significant morbidity and mortality. Previous studies
from Oman have provided ARPKD-associated morbidity
data but lacked molecular genetic data [10, 23]. In this
study we have provided a clinical and molecular genetic
analysis of PKHD1 in a cohort of 40 patients, obtaining
a molecular genetic diagnosis in 38 patients with clinic-
ally suspected ARPKD.
Table 3 Allele frequencies and worldwide distribution of the four PKHD1 mutations detected in Omani ARPKD patients
Location Exon 3 Exon 6 Exon 32 Exon 58
Nucleotide variation c.107C > T c.406A > G c.4870C > T c.9370C > T
Amino acid variation p.T36M p.T136A p.R1624W p.H3124Y
dbSNP ID rs137852944 NA rs200391019 rs1554218666
MAF ExAC 0.0005193 (63/121312) not found 0.0001812 (22/121394) not found
1000
Genomes
Project
0.000199 (1/5008) not found not found not found
gnomAD
(total)
0.0005094 (144/282706) not found 0.0001379 (39/282816) not found
ESP (Exome
Variant Server)
0.00031 (4/13006) not found 0.00015 (2/13006) not found
ClinVar (global
MAF)
0.0002 not found NA NA
UK 10 K 0.00054 (4/7428) not found 0.00013 (1/7428) not found
Genomics England,
100,000G project
16× not found 6× not found
PKHD1 mutation
database
86× not found 15× 4×
Origin Germany, Caucasian-American,
UK, Spain, Czech Republic, Finland,
Netherlands, Australia, Oman
Oman Saudi-Arabia, Caucasian-American,
Israel, Netherlands, Czech Republic,
Finland-Greece, Oman
Italy, Turkey, Oman
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Most study patients had early onset ARPKD disease
reflected by age at initial diagnosis. Five were diagnosed
prenatally, 24 before their first year of life and 11 during
childhood. These early-onset phenotypes are in agree-
ment with that reported from other studies [22]. Clinical
analysis of our ARPKD patients showed that the fre-
quently associated morbidities were also common in our
patients including systemic hypertension, congenital
hepatic fibrosis, splenomegaly, pulmonary hypoplasia
and CKD. 15% of studied patients died during the peri-
natal or neonatal period due to respiratory deficiency,
which is similar to the death rate during the first year of
life reported by Bergmann [22]. It is estimated that 30–
50% of ARPKD patients die shortly after birth due to re-
spiratory failure, whereas kidney failure is a rare cause of
neonatal death [24]. With the advancement in renal re-
placement therapy modalities, the survival rate of neo-
nates and children with ARPKD is improved. In our
patients, 12 (30%) developed ESKD by median age of 13
years and hence required either renal replacement ther-
apy (n = 8) or kidney transplantation (n = 4) (Table 2).
As the PKHD1 is a large gene and in order to iden-
tify the causative mutations in our ARPKD patients,
we had previously applied targeted NGS gene panel
for 18 unrelated patients (Table 2) [12]. Four mis-
sense mutations in PKHD1 were identified as genetic
causes of ARPKD in this cohort, with the mutations
identified within exons 3, 6, 32 and 58. Therefore, we
proceeded with a targeted exon PCR diagnostics ap-
proach with Sanger sequencing of these exons alone
for the molecular diagnosis of other ARPKD patients
(n = 20) from 14 different families. In total, 30 out of
32 suspected ARPKD families were solved with bialle-
lic changes in PKHD1, achieving a diagnostic rate of
94%, hence providing cost effective targeted PCR ana-
lysis of these specific alleles as a convenient diagnos-
tic tool. Failure to detect mutations in two unrelated
probands using the Sanger screening approach alone
may be explained by the heterogeneity of the ARPKD
disease where mutations may lay in other exons or
indeed in other recessive cystogenes that phenocopy
ARPKD. None of the unsolved patients had have fam-
ily history of kidney disease, therefore mutations in
autosomal recessive genes that lead to ARPKD-like
phenotypes such as the DZIP1L [8] or even in domin-
ant cystic kidney disease genes such as HNF1B, PKD1
and PKD2 that often occur de novo are possible [25].
Whole exome sequencing approaches that would
allow inclusion of genes such as DZIP1L are the sug-
gested option for these unsolved patients. With the
current improvements of high throughput sequencing
of different renal ciliopathy genes, it is anticipated
Fig. 1 Geographical distribution of the 4 missense PKHD1 mutations in ARPKD patients from Oman. Each family is presented by plot. Each
different mutation is indicated by a different colour. Map sourced through www.freeusandworldmaps.com and modified using
www.vectorstock.com software.
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that the majority of patients with cystic kidney dis-
ease phenotypes can receive a precise molecular gen-
etic diagnosis.
To date, 748 unique PKHD1 variants have been
recorded in the Human ARPKD/PKHD1 Mutation
Database (http://www.humgen.rwth-aachen.de/index.
php). Approximately 45% of these variants are missense
alterations resulting in substitution of conserved amino
acids, which usually leads to partial or complete dysfunc-
tion of fibrocystin. All of the PKHD1 variants in this
study are missense alterations of highly conserved amino
acids. Although three of these variants are reported in
the ARPKD / PKHD1 Mutation Database, p. (Thr36Met)
is the most persistent mutation found in PKHD1 in
ARPKD patients to date. Structurally, fibrocystin is an
integral membrane protein consisting of a large amino
terminal extracellular domain (about 3860 aa) containing
various glycosylation sites, a single transmembrane seg-
ment and a short cytoplasmic C-terminal tail (about 195
aa) comprising four potential protein kinase A phos-
phorylation sites [3] (Supplementary Figure S2B). The
localization of fibrocystin to primary cilia and its integral
structure predicted a sensory role at which fibrocystin
acts as receptor transducing the extracellular informa-
tion into the cell through stimulation of signal cascades,
thus controlling cell-cell adhesion and proliferation [3].
The 4 missense variants identified in this study are lo-
cated in exons encoding the extracellular domain (Sup-
plementary Figure S2C) and are either very rare or not
observed in the reference databases of healthy controls
(including ExAC, gnomAD, 1000G project (Table 3)).
In the Omani population our previous NGS studies
did not find PKHD1 truncating mutations that have
been described in patients with perinatal lethal pheno-
types [22, 26]. The most frequent change identified in
Omani families was p.(Thr36Met) located in exon 3, de-
tected homozygously in 16 families and heterozygously
in 8 families, accounting for almost 75% of the families.
Patients with homozygous p.(Thr36Met) change (n =
18) had an earlier age of onset and an increased severity
of disease (6 had a severe perinatal presentation and died
before 1 year of life, while the remaining had either in-
fantile or early childhood presentation leading to ESKD)
(Table 2). Consistent with observations made by
Bergman et al. [26], the p.(Thr36Met) variant may lead
to variability in the age of onset and severity of disease.
Additionally, p.(Thr36Met) in combination with the mis-
sense changes p.(Thr136Ala) and p.(Arg1624Trp) in
some of our cases caused a relatively severe form of
ARPKD, which is in agreement with previous reported
studies [21, 27, 28].
The relatively common pathogenic PKHD1 allele
p.(Thr36Met) has been described in many populations
and ethnicities. Whether this allele is a highly conserved
ancestral change that is frequent in some populations
such as the Central European population [15, 27], or
caused by recurrent mutational events is uncertain [22].
The p.(Thr36Met) allele appears to be common in Euro-
pean genomes, with an expected carrier frequency of 1:
412 [29]. However, detections of this change in patients
from different ethnicities and origins are suggestive that
p.(Thr36Met) is a PKHD1 ‘hotspot’ mutation caused by
the frequent methylation events of cytosine to thymine
in the CpG sites [17, 27]. It is also assumed that the sub-
stitution of the amino acid Threonine to Methionine
creates a potential alternative translation start codon
that may be even stronger than the original start codon
[21]. The protein product initiating from position c.107
would be predicted to lead to complete loss of protein
function due to improper protein folding [21].
The missense change, p.(Arg1624Trp), was previously
reported in patients from different ethnicities, including
Caucasian Americans [17, 19], Dutch [18], Czech Repub-
licans [28], Slovenians [30], Saudi Arabians [17, 31, 32]
and Kuwaitis [33]. The p.(Arg1624Trp) mutation has
been described with late onset or older ARPKD presen-
tations when present homozygously [17, 31] and hetero-
zygously in trans with other truncating or missense
change [17, 30]. In contrast, 6 of our patients with the
p.(Arg1624Trp) mutation developed clinical features of
ARPKD in infancy, 5 presented during childhood period
and 1 at 11 years of age. The p.(His3124Tyr) combined
with p.(Arg1624Trp) was found in a 26 year old patient
with stage 4 CKD, who was initially diagnosed with poly-
cystic kidney disease in early childhood (Table 2). These
findings are in contrast to those made by Bergmann
et al. [16] and Gunay-Aygun [19] that correlated
p.(His3124Tyr) with a severe perinatal-fatal phenotype.
These results therefore demonstrate that establishing
genotype-phenotype correlations in ARPKD is challen-
ging. Any correlation is complicated by the large number
of missense variants distributed over the entire length of
the coding exons of PKDH1 and its complex splicing
pattern [3]. It was believed that two truncating muta-
tions are associated with severe perinatal lethality and at
least the presence of one missense is required for sur-
vival beyond the neonatal period. However, evidence is
accumulating on the increased pathogenicity of some
missense mutations that may cause complete loss of
function effects [22]. The wide variability in ARPKD se-
verity among patients may in part be explained by differ-
ences in PKHD1 mutations, influences of modifiers
genes and environmental factors [25].
ARPKD is generally a severe form of pediatric ciliopa-
thy with recognized phenotypic variability. While a sig-
nificant number of ARPKD patients surviving the
neonatal period reaches adulthood, some patients have
an adulthood presentation and their kidney function
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ranges from normal to moderate kidney insufficiency to
ESKD [34]. Although bilateral kidney enlargement with
multiple cysts is the major clinical characteristic, liver
manifestations may lead to symptomatic disease compli-
cations in ARPKD patients. Liver disease tends to mani-
fest later than kidney disease typically with progressive
hepatic fibrosis and portal hypertension [34]. Hypers-
plenism, portal hypertension, and variceal bleeding are
major liver involvements that may develop as a result of
progressive liver fibrosis. In rare cases, both kidney and
liver disease may present in late adolescence or in adult-
hood [35]. The low prevalence, limited clinical informa-
tion and atypical sonographic pattern of adult ARPKD
patients can challenge the clinical diagnosis and manage-
ment, hence genetic testing may be demanded for the
establishment of definite diagnosis [36]. In this study,
the absence of late presenting ARPKD in our cohort
may be due to recruiting predominantly cystic kidney
disease phenotypes.
The Omani population is characterized by a unique
structure of tribal communities occupying definite geo-
graphical regions. This structure is conserved over many
generations and has created genetic isolates [37]. The
custom of consanguineous marriages as well as within-
tribe (endogamous) marriages are extremely conserved
in Oman, accounting for 56.3% [38] and 20.4% of total
marriages, respectively [39]. Over 300 genetic diseases
have been identified in the Omani population [40]. The
high frequency of recessive disorders in this population
is probably related to a combination of genetic drift,
consanguinity, and geographical isolation. The detection
of only 4 pathogenic variants in different geographical
regions of the country may be explained by the presence
of PKHD1 founder alleles and reveals a high degree of
homogeneity in this population. Similarly, genetic stud-
ies of population isolates such as Finnish, French, Ash-
kenazi Jews and Africans represent a powerful method
of finding founder mutations in PKHD1, which can be
utilized for efficient diagnostic testing of at-risk individ-
uals and pregnancies in these populations (Supplemen-
tary Table S3) [27, 41–43].
Currently there is no clinical cure for ARPKD other
than managing the clinical complications [34]. Together
translational research and clinical trials in patients may
facilitate successful drug development in coming future.
With the absence of clinical biomarkers and lack of
comprehensive assessment of the available therapeutic
options for ARPKD patients on one hand and great mor-
bidity and mortality of disease on the other hand, there
is a serious need for prospective and retrospective popu-
lation studies and construction of an international clin-
ical database. Such effort can elaborate the current
understanding of ARPKD and deliver more information
on extrarenal manifestations and treatment options.
Recently, the German Society for Pediatric Nephrology
(GPN) and the European Study Consortium for Chronic
Kidney Disorders Affecting Pediatric Patients (ESCAPE)
collaborated to initiate an international multicenter
registry of ARPKD (ARegPKD) [44]. The continued
identification of PKHD1 variants and their associated
phenotypes is to be promoted and inclusion of cohorts
from different ethnicities is valuable and should be
encouraged.
Conclusions
In conclusion, this study shows that prior NGS identifi-
cation of PKHD1 mutations and subsequent screening of
only 4 exons of the PKHD1 gene was sufficient to iden-
tify the expected causative alleles in 94% of the studied
families and was suggestive of founder effects in this
gene. There are many advantages for identifying high
frequency limited disease associated mutations in a
population, including simplifying the diagnostic testing,
providing genetic counseling for individuals at risk and
allowing rapid detection of mutations in other family
members.
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